HCG 10,000iu

This guide covers the 10000IU vial format of HCG — the same heterodimeric glycoprotein hormone described in the dedicated 5000IU guide (α-subunit + β-subunit, ~36–40 kDa total, bioactivity rated in International Units against a WHO standard), supplied at double the per-vial bioactivity. The molecule, the receptor target (LHCGR), and the proposed research mechanisms are identical to the 5000IU form. What this guide adds is the practical context for protocols that consume more than 5000IU of bioactivity per reconstitution and the bioactivity-consistency considerations that come with preparing larger working volumes.

HCG research at multi-subject scale frequently exceeds the 5000IU vial's per-reconstitution working volume. Animal-model studies involving multiple subjects, cohort reproductive-endocrinology protocols, and any design that requires consistent stock-solution preparation across many parallel experiments all benefit from the larger vial format. Beyond reducing the number of reconstitution events, drawing all working aliquots from a single batch and a single reconstitution improves between-aliquot bioactivity consistency — which matters more for glycoproteins than for synthetic peptides because glycoform-related bioactivity variation is one of the larger sources of HCG inter-batch variability.

HCG 10000IU is sold strictly for laboratory and research use. It is not approved by the FDA or any other regulatory body for human or veterinary use, and nothing in this guide constitutes guidance for human administration.

Different batches of HCG can carry subtly different glycoform mixtures, and the WHO-traceable IU rating represents an average bioactivity at the time of certification. Across a multi-subject research protocol, drawing aliquots from a single 10000IU vial — rather than from two or three 5000IU vials potentially drawn from different batches — keeps the glycoform mixture identical across all experimental subjects. This matters most when the experimental endpoint is itself sensitive to small differences in receptor-activation kinetics, which is the case for several reproductive-endocrinology readouts.

Every batch of MHS Longevity HCG 10000IU is submitted to an independent third-party laboratory before release — the same immunoreactive-content + bioactivity-assay protocol applied to the 5000IU vial, with the same WHO reference standard:

Lyophilized HCG stability at -20°C is comparable across vial sizes. The handling change for the 10000IU vial is post-reconstitution: a single reconstitution yields more total working bioactivity than the 5000IU vial, which makes single-use aliquoting both more practical and more impactful for between-aliquot consistency. Glycoproteins are particularly sensitive to repeated freeze–thaw cycles compared to synthetic peptides; the larger vial format benefits especially from immediate aliquoting at -20°C. Standard aseptic technique applies during reconstitution.